Simple Summary Patients with advanced melanoma are often treated with v-raf murine
sarcoma viral oncogene homolog B1 (BRAF) inhibitors. Although these agents prolong life …

In this review, we analyse the impact of oncogenic Ras mutations in mediating cancer drug
resistance and the progress made in the abrogation of this resistance, through …

Severe cutaneous adverse reactions (SCARs)[Stevens–Johnson syndrome (SJS), toxic
epidermal necrolysis (TEN), drug rash with eosinophilia and systemic syndrome (DRESS) …

Background Sorafenib is a current first-line treatment option for advanced hepatocellular
carcinoma (HCC). This study aimed to evaluate the impact of early adverse events (AEs) …

Introduction. Afatinib is a first‐line treatment option for patients with an advanced nonsmall
cell lung cancer (NSCLC) expressing an epidermal growth factor receptor (EGFR) activating …

Die zielgerichteten Therapien, wie BRAF-und MEK-Inhibitoren, werden primär bei Patienten
mit fortgeschrittenem malignem Melanom und einer BRAF-Mutation eingesetzt (3, S. 128) …

Background The combination of BRAF and MEK inhibitors has become standard of care in
the treatment of metastatic BRAF V600-mutated melanoma. Clinical factors for an early …

Intra-cellular signalling determines how cells process information. Through the integration of
diverse chemical and physical stimuli, cells can enact transcription, among other changes to …

The introduction of BRAF inhibitors dramatically improved the outcome of patients
diagnosed with metastatic melanoma harboring BRAF mutation. The later addition of MEK …

O câncer é considerado uma doença multifactorial causada por uma proliferação celular
anormal e apresenta um impacto econômico no sistema de saúde a nível mundial. Os tipos …